timeless circadian regulatorGenealiases: FASPS4 · TIM · TIM1 · hTIM
Q-omics provides the consensus-scored TIMELESS profile across patient tissues and cancer cell-line models. TIMELESS expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TIMELESS is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TIMELESS RNA expression shows 23,268 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where TIMELESS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TIMELESS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TIMELESS survival associations across molecular data types. TIMELESS RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TIMELESS RNA expression–survival associations across cancer types. High TIMELESS expression shows unfavorable associations in ACC, MESO, LIHC, KIRC, UVM and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TIMELESS RNA expression.
This table summarizes TIMELESS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TIMELESS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TIMELESS shows higher tumor expression in HNSC, BLCA, KIRP, COAD, LUAD and LIHC. The HNSC box plot shows higher TIMELESS RNA expression in tumor versus normal tissue (log2 FC = +1.746, t-test p < 0.001).
This table shows molecular features associated with TIMELESS in patient tissues and cancer cell lines. In patient samples, TIMELESS shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TIMELESS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
